ZORYA
LIVE

Serial Number

79371681

Owner

CYTOO

Attorney

Steven J. Solomon

Filing Date

Dec 7, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ZORYA Trademark

Serial Number: 79371681 • Registration: 7484026

ZORYA is a trademark filed by CYTOO on December 7, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

CYTOO (7 trademarks)

7 Parvis Louis Néhel,

Entity Type: 99

Trademark Details

Filing Date

December 7, 2022

Registration Date

August 27, 2024

Published for Opposition

June 11, 2024

Goods & Services

Quality control and testing devices namely culture plates to test and conduct quality control in the field of biology, biotechnology and pharmacy; downloadable software for the collection, processing and analysis of data in the field of biotechnology and pharmacy; scientific laboratory instruments, namely computer hardware and downloadable software for data analysis, database management, data processing, in the field of life science research and the pharmaceutical industry market and diagnostics

Pharmaceutical products, namely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; Veterinary products, namely veterinary preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; Sanitary products for medicine, namely sanitary preparations for medical use; Chemical and biological preparations for medical use, namely pharmaceutical preparations for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity , diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases; chemical and biological preparations for pharmaceutical use for the prevention and the treatment of muscle dysfunction associated diseases, muscle dystrophies, muscle metabolic diseases, muscle atrophy associated diseases, sarcopenia, cancer, cachexia, obesity, diabetes and cardiovascular diseases, renal diseases, nephropathies, neuropathies, retinopathies, neurodegenerative, psychiatric and cognitive diseases, metabolic diseases, inflammatory diseases

Medical, biotechnological, and pharmaceutical research; research and development of chemical, biological and scientific products and materials in the biological, biotechnological, medical, diagnostic and pharmaceutical fields; scientific research, advisory and information services in the medical, biotechnological, pharmaceutical, diagnostic, technological and industrial fields; design and development of computers, software and computer platforms; technical testing namely technological testing in the scientific, biological, biotechnological and medical fields and quality control services of goods and services; advisory services with respect to quality testing, technical testing namely, technological testing in the scientific, biological, biotechnological and medical fields and scientific and medical clinical trials; services for scientific development and analysis of cell tests; scientific and medical research and development of products and services in the field of imaging, in the scientific, biological, biochemical, molecular-biology, biotechnological and medical fields; Scientific interpretation and analysis of data by imaging in the scientific, biological, biochemical, molecular-biology, biotechnological and medical fields; diagnostic and industrial research in the biological, biotechnological and medical fields

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 15, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 22, 2025 FICS
FINAL DISPOSITION PROCESSED
Feb 21, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 27, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 27, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 27, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 11, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 11, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 22, 2024 NONP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 12, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 12, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 12, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 12, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 12, 2024 COAR
APPROVED FOR PUB - PRINCIPAL REGISTER
May 6, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
May 6, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 6, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
May 6, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 6, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 6, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 4, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 4, 2024 TROA
REFUSAL PROCESSED BY IB
Oct 25, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 4, 2023 RFCS
REFUSAL PROCESSED BY MPU
Oct 4, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 25, 2023 RFCR
NON-FINAL ACTION WRITTEN
Sep 24, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 13, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 16, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 12, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 8, 2023 REPR